Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Summary

This study aims to compare the efficacy and safety of lenalidomide plus CHOP (L-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL)

Conditions

• Peripheral T-Cell Lymphoma
• Lenalidomide
• CHOP

Interventions

DRUG

Lenalidomide

25mg po on day 1-10

DRUG

Cyclophosphamide

750mg/m² iv on day1

DRUG

Doxorubicin

50mg/m² iv on day 1

DRUG

Vincristine

1.4mg/m² iv on day 1

DRUG

Prednisone

100mg po on day1-5

Sponsors & Collaborators

• Ruijin Hospital

  collaborator OTHER

• Xinqiao Hospital of Chongqing

  collaborator OTHER

• Union hospital of Fujian Medical University

  collaborator OTHER

• Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

  collaborator OTHER

• Southern Medical University, China

  collaborator OTHER

• Shandong Provincial Hospital

  collaborator OTHER_GOV

• Huashan Hospital

  collaborator OTHER

• First Hospital of China Medical University

  collaborator OTHER

• Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

  collaborator OTHER

• Henan Provincial People's Hospital

  collaborator OTHER

• First Affiliated Hospital Xi'an Jiaotong University

  collaborator OTHER

• Changhai Hospital

  collaborator OTHER

• The Affiliated Hospital of Xuzhou Medical University

  collaborator OTHER

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• RenJi Hospital

  collaborator OTHER

• Zhongda Hospital

  collaborator OTHER

• The First Affiliated Hospital of Anhui Medical University

  collaborator OTHER

• Hunan Cancer Hospital

  collaborator OTHER

• First Affiliated Hospital of Harbin Medical University

  collaborator OTHER

• Xiangya Hospital of Central South University

  collaborator OTHER

• The First Affiliated Hospital of Dalian Medical University

  collaborator OTHER

• Jilin Provincial Tumor Hospital

  collaborator OTHER

• Shanxi Province Cancer Hospital

  collaborator OTHER

• Zhongshan Hospital Xiamen University

  collaborator OTHER

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-04-01

Primary Completion

2023-12-31

Completion

2026-12-31

Countries

• China

Study Locations